JP2023511434A5 - - Google Patents

Info

Publication number
JP2023511434A5
JP2023511434A5 JP2022544734A JP2022544734A JP2023511434A5 JP 2023511434 A5 JP2023511434 A5 JP 2023511434A5 JP 2022544734 A JP2022544734 A JP 2022544734A JP 2022544734 A JP2022544734 A JP 2022544734A JP 2023511434 A5 JP2023511434 A5 JP 2023511434A5
Authority
JP
Japan
Prior art keywords
nucleotides
nucleotide
dsrna agent
chain
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022544734A
Other languages
English (en)
Japanese (ja)
Other versions
JP7826211B2 (ja
JP2023511434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/014729 external-priority patent/WO2021150969A1/en
Publication of JP2023511434A publication Critical patent/JP2023511434A/ja
Publication of JP2023511434A5 publication Critical patent/JP2023511434A5/ja
Application granted granted Critical
Publication of JP7826211B2 publication Critical patent/JP7826211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022544734A 2020-01-24 2021-01-22 ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法 Active JP7826211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062965452P 2020-01-24 2020-01-24
US62/965,452 2020-01-24
US202163138717P 2021-01-18 2021-01-18
US63/138,717 2021-01-18
PCT/US2021/014729 WO2021150969A1 (en) 2020-01-24 2021-01-22 LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026027981A Division JP2026131037A (ja) 2020-01-24 2026-02-25 ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2023511434A JP2023511434A (ja) 2023-03-17
JP2023511434A5 true JP2023511434A5 (cg-RX-API-DMAC7.html) 2024-01-30
JP7826211B2 JP7826211B2 (ja) 2026-03-09

Family

ID=76992618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544734A Active JP7826211B2 (ja) 2020-01-24 2021-01-22 ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法

Country Status (12)

Country Link
US (1) US20230126233A1 (cg-RX-API-DMAC7.html)
EP (1) EP4093872A4 (cg-RX-API-DMAC7.html)
JP (1) JP7826211B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220133246A (cg-RX-API-DMAC7.html)
CN (1) CN115298312A (cg-RX-API-DMAC7.html)
AU (1) AU2021211723A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014590A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168871A1 (cg-RX-API-DMAC7.html)
IL (1) IL294728A (cg-RX-API-DMAC7.html)
MX (1) MX2022009026A (cg-RX-API-DMAC7.html)
TW (1) TW202142690A (cg-RX-API-DMAC7.html)
WO (1) WO2021150969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712891A (zh) * 2023-06-20 2026-03-20 阿达尔克斯制药有限公司 Lrrk2调节组合物及其使用方法
CN122074089A (zh) * 2023-09-27 2026-05-22 三晟医药公司 新型siRNA构建体、治疗剂和修饰
CN120082552A (zh) * 2023-12-01 2025-06-03 艾码生物科技(南京)有限公司 初级-miRNA及其应用
WO2025190385A1 (zh) * 2024-03-14 2025-09-18 上海拓界生物医药科技有限公司 靶向LRRK2的RNAi剂及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124096A2 (en) * 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
GB201004475D0 (en) * 2010-03-17 2010-05-05 Isis Innovation Gene silencing
TWI664187B (zh) * 2013-05-22 2019-07-01 阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
EP3377629B1 (en) * 2015-11-18 2023-07-05 Rosalind Franklin University of Medicine and Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
TWI833770B (zh) * 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Similar Documents

Publication Publication Date Title
JP7805386B2 (ja) Lpa発現を阻害するための組成物及び方法
JP2023521604A5 (cg-RX-API-DMAC7.html)
JP2022515193A5 (cg-RX-API-DMAC7.html)
TWI727963B (zh) 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關疾病之使用方法
JP2023523993A5 (cg-RX-API-DMAC7.html)
JP7830319B2 (ja) ハンチンチン(HTT)iRNA剤組成物およびその使用方法
CN115397436B (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
JP7863095B2 (ja) Snca関連神経変性疾患を治療又は予防するためのsnca irna組成物及びその使用方法
TW201831685A (zh) 使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
JP2022501057A5 (cg-RX-API-DMAC7.html)
CN108186667A (zh) RNAi试剂、组合物及其用于治疗甲状腺素运载蛋白(TTR)相关疾病的使用方法
JP2024536811A5 (cg-RX-API-DMAC7.html)
IL294728A (en) lrrk2 RNA material preparations and methods of using them
JP2023544413A5 (cg-RX-API-DMAC7.html)
JP2024528503A5 (cg-RX-API-DMAC7.html)
US20240401059A1 (en) Compositions and methods for modulating pnpla3 expression
JP7560616B2 (ja) 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法
JP2018504380A (ja) Reversir(商標)化合物
JP2024522068A5 (cg-RX-API-DMAC7.html)
JP2024509783A5 (cg-RX-API-DMAC7.html)
TW202328447A (zh) 用於降低dmpk表現之化合物與方法
TW202305134A (zh) 杭丁頓蛋白(HTT)iRNA劑組成物及其使用方法
JP2025507372A5 (cg-RX-API-DMAC7.html)
JP2024521907A5 (cg-RX-API-DMAC7.html)
TW202330920A (zh) 用於調節apoc3表現之組合物及方法